Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT04463251
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 102 participants
- Sponsor
- R-Pharm Overseas, Inc.
- Registry
-
NCT04463251
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Russia
- Registry status
- Completed
Technical summary
Registry record NCT04463251. Randomized; double masking; primary purpose treatment. Start 2020-12-07 (actual); primary completion 2021-11-03 (actual). Results posted on 2024-01-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
- Condition
- Acute ST Segment Elevation Myocardial Infarction
- Intervention (Biological)
- RPH-104 80 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- R-Pharm Overseas, Inc.
- Collaborator
- Cromos Pharma LLC
- Collaborator
- Data Management 365
- Collaborator
- Keystat, LLC
- Collaborator
- R-Pharm
- Collaborator
- K-Research, LLC
Record details
- Record id
cardio:ct-nct04463251- Content hash
3c9d6be0566030ae740513f9c1a3f2e19d8838a73c8556c7d0793b451f6a8f8a